pDONR223-MAP4K1 Citations (2)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-MAP4K1
| Articles |
|---|
| A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation. Gonzalez Quesada Y, DesGroseillers L. Int J Mol Sci. 2022 Sep 30;23(19):11588. doi: 10.3390/ijms231911588. PubMed |
| HPK1 Dysregulation-Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression. Choi WS, Kwon HJ, Yi E, Lee H, Kim JM, Park HJ, Choi EJ, Choi ME, Sung YH, Won CH, Sung CO, Kim HS. Adv Sci (Weinh). 2024 Aug;11(29):e2400920. doi: 10.1002/advs.202400920. Epub 2024 Jun 3. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.